At a glance
ClinicalIndex Comparison RecordPhase 3Active· 670 enrolled
Drug / intervention
Deucravacitinib +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Deucravacitinib in Participants With Active Psoriatic Arthritis Who Are Naïve to Biologic Disease-modifying Anti-rheumatic Drugs
In Brief
A Phase 3 clinical trial evaluating Deucravacitinib and Placebo for Psoriatic Arthritis. Active but no longer recruiting, targeting 670 participants across 183 sites in 21 countries.
Detailed Summary
The purpose of this study is to evaluate the efficacy and safety of deucravacitinib versus placebo in participants with active psoriatic arthritis who are naïve to biologic disease-modifying anti-rheumatic drugs. The long term extension period will provide additional long-term efficacy and safety information.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPsoriatic Arthritis
CountriesArgentina, Australia, Brazil, Bulgaria, Chile, China, Colombia, Czechia, Finland, France, Hungary, Ireland, Italy, Mexico, Poland, Romania, Russia, Spain, Taiwan, United Kingdom, United States
Collaborators--
Timeline
Phase 3Active
202220232024202520262027
First PostedJun 2021
Enrollment StartJul 2021
Primary CompletionSep 2024
TodayJul 2026
Study CompletionJun 2027
First PostedJun 1, 2021
Enrollment StartJul 13, 2021
Primary CompletionSep 5, 2024
Study CompletionJun 10, 2027
TodayJul 2, 2026
Enrollment to primary: 3.1 yearsPosted 5.1 years ago
Interventions
Deucravacitinibdrug
Specified dose on specified days
Placeboother
Specified dose on specified days